- Home
- AUST vs HOTH Comparison
AUST vs HOTH Comparison
Compare AUST & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- HOTH
- Stock Information
- Founded
- AUST 2020
- HOTH 2017
- Country
- AUST Canada
- HOTH United States
- Employees
- AUST N/A
- HOTH N/A
- Industry
- AUST
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- HOTH Health Care
- Exchange
- AUST Nasdaq
- HOTH Nasdaq
- Market Cap
- AUST 22.2M
- HOTH 18.0M
- IPO Year
- AUST 2022
- HOTH 2019
- Fundamental
- Price
- AUST $1.75
- HOTH $1.22
- Analyst Decision
- AUST
- HOTH Strong Buy
- Analyst Count
- AUST 0
- HOTH 2
- Target Price
- AUST N/A
- HOTH $4.50
- AVG Volume (30 Days)
- AUST 89.9K
- HOTH 296.6K
- Earning Date
- AUST 11-06-2025
- HOTH 11-12-2025
- Dividend Yield
- AUST N/A
- HOTH N/A
- EPS Growth
- AUST N/A
- HOTH N/A
- EPS
- AUST N/A
- HOTH N/A
- Revenue
- AUST N/A
- HOTH N/A
- Revenue This Year
- AUST N/A
- HOTH N/A
- Revenue Next Year
- AUST N/A
- HOTH N/A
- P/E Ratio
- AUST N/A
- HOTH N/A
- Revenue Growth
- AUST N/A
- HOTH N/A
- 52 Week Low
- AUST $1.05
- HOTH $0.66
- 52 Week High
- AUST $2.94
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- AUST 52.71
- HOTH 46.05
- Support Level
- AUST $1.42
- HOTH $1.14
- Resistance Level
- AUST $1.69
- HOTH $1.22
- Average True Range (ATR)
- AUST 0.17
- HOTH 0.08
- MACD
- AUST 0.02
- HOTH 0.01
- Stochastic Oscillator
- AUST 88.01
- HOTH 72.16
About AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).